Delving into the Latest Updates on Hangzhou Grand Biologic Pharmaceutical Inc. with Synapse

Overview

Basic Info

Introduction

Hangzhou Longda Xinke Bio-Pharmaceutical Co Ltd. operates as a national high-tech company deeply involved in the research, development, manufacture, and commerce of biopharmaceutical technology and related products. This entity has marked its presence in the Zhejiang province as an organization dedicated to the development and manufacturing of microecological preparations. Established in December 2004, Hangzhou Longda Xinke has built itself upon the cultural tenets of loyalty, simplicity, diligence, and innovation.

Tags

Other Diseases

Digestive System Disorders

Immune System Diseases

Probiotics

Monoclonal antibody

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Probiotics	2
Monoclonal antibody	1
Live biotherapeutic products	1
Enzyme	1

Top 5 Target	Count

α4β7(Integrin alpha-4/beta-7)	1
Uric acid	1

主要目的： 1) 评价HZBio1在痛风受试者中多次给药的安全耐受性； 2) 评价HZBio1在痛风受试者中多次给药的药代动力学（PK）特征。次要目的： 1）初步评价HZBio1在痛风受试者中多次给药的药效动力学（PD）特征； 2）初步评价HZBio1在痛风受试者体内多次给药的免疫原性。

[Translation]

Primary objectives: 1) To evaluate the safety and tolerability of HZBio1 after multiple administration in gout subjects; 2) To evaluate the pharmacokinetic (PK) characteristics of HZBio1 after multiple administration in gout subjects. Secondary objectives: 1) To preliminarily evaluate the pharmacodynamic (PD) characteristics of HZBio1 after multiple administration in gout subjects; 2) To preliminarily evaluate the immunogenicity of HZBio1 after multiple administration in gout subjects.

Start Date17 Nov 2022

Sponsor / Collaborator

Chongqing Paijin Biotechnology Co Ltd.

[+1]

100 Clinical Results associated with Hangzhou Grand Biologic Pharmaceutical Inc.

Login to view more data

0 Patents (Medical) associated with Hangzhou Grand Biologic Pharmaceutical Inc.

Login to view more data

100 Deals associated with Hangzhou Grand Biologic Pharmaceutical Inc.

Login to view more data

100 Translational Medicine associated with Hangzhou Grand Biologic Pharmaceutical Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Phase 2 Clinical

1

2

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Clostridium Butyricum (Grand Life Science)	Acute diarrhea More	Approved
Combined Bifidobacterium ,Lactobacillus,Enterococcus And Bacillus (Grand Biologic)	Diarrhea More	Approved
Pegylated recombinant uricase(Chongqing Paijin Biotechnology Co Ltd) ( Uric acid )	Gout More	Phase 2
HZBio-2	Crohn Disease More	Phase 1
CN113813377 ( α4β7 )	Gastrointestinal Diseases More	Discovery